TargetMol

Pridopidine hydrochloride

Product Code:
 
TAR-T7352L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7352L-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7352L-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7352L-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pridopidine Hydrochloride is a dopaminergic stabilizer that has been shown to improve a variety of neurological and psychiatric disorders, including Huntington's disease. Pridopidine Hydrochloride stabilizes psychomotor activity in a state-dependent way through the dual effects of functional dopamine D2 receptor antagonism and cortical glutamate enhancement.
CAS:
882737-42-0
Formula:
C15H24ClNO2S
Molecular Weight:
317.87
Purity:
0.98
SMILES:
Cl.CCCN1CCC(CC1)c1cccc(c1)S(C)(=O)=O

References

Shannon KM. Pridopidine for the treatment of Huntington's disease. Expert Opin Investig Drugs. 2016;25(4):485-92. doi: 10.1517/13543784.2016.1153627. Epub 2016 Mar 10. PubMed PMID: 26881734. Unti E, Mazzucchi S, Palermo G, Bonuccelli U, Ceravolo R. Antipsychotic drugs in Huntington's disease. Expert Rev Neurother. 2016 Aug 23:1-11. [Epub ahead of print] PubMed PMID: 27534434. Squitieri F, de Yebenes JG. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Des Devel Ther. 2015 Oct 28;9:5827-33. doi: 10.2147/DDDT.S65738. eCollection 2015. PubMed PMID: 26604684; PubMed Central PMCID: PMC4629959. Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR. Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Hum Mol Genet. 2016 Jul 27. pii: ddw238. [Epub ahead of print] PubMed PMID: 27466197.